Industry

LOS ANGELES–(BUSINESS WIRE)–Sinclair Kennally, CNHP, CNC, founder and CEO of Detox Nation, proudly announces the relaunch of its wellness experience, the Rapid Liver Reset Program, now upgraded with new tools, expert support, and deeper accountability to help participants reset their liver, restore energy, and revitalize overall health in just four weeks. This science-backed program is … [Read more…]

AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell’s deep expertise and track record. LONDON & NEW YORK–(BUSINESS WIRE)–ViroCell Biologics (“ViroCell”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration … [Read more…]

MARSEILLE, France–(BUSINESS WIRE)–#IRConference–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the company’s CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. BTIG, a global financial services firm specializing in investment banking, institutional trading, research … [Read more…]

New product covers cancer, heart attack, stroke, and more DES MOINES, Iowa–(BUSINESS WIRE)–Wellabe has launched a new Critical Illness insurance product in 14 states1 to protect the well-being of customers when they suffer from cancer, heart attack, stroke, or other critical illnesses. Underwritten by Medico® Insurance Company, Wellabe’s Critical Illness insurance provides customizable coverage for … [Read more…]

EVANSTON, Ill.–(BUSINESS WIRE)–Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines, today announced the appointment of Barry Labinger as Chief Executive Officer. With more than three decades of executive experience in the biopharmaceutical industry, Barry brings a proven track record of building and leading innovative life sciences organizations through critical … [Read more…]

With 128 winners transforming 400 million lives around the world, the Prize continues to attract the world’s most pioneering sustainability solutions. 30% surge in global entries highlights the Prize’s growing impact in advancing transformative solutions across health, food, water, energy, and climate action. AI-powered solutions, disruptive innovations, and technologies that expand access to essential services … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) – Global Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. The global exosome research market is projected to reach USD 480.6 million by 2030 from USD 214.4 million … [Read more…]

DALLAS–(BUSINESS WIRE)–HealthMark Group (“HealthMark” or “the Company”), a leading provider of clinical information exchange solutions for healthcare providers, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. This partnership aims to accelerate HealthMark’s growth as the Company advances its mission to optimize the exchange of healthcare data through … [Read more…]

Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union OSAKA, Japan & WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines, and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), … [Read more…]

BEIJING–(BUSINESS WIRE)–#AntibodyDiscovery–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full … [Read more…]